Pfizer's COVID-19 vaccine shows early promise in global trials
The drugmaker Pfizer recently announced that early results from the global trials of a new COVID-19 vaccine showed it was 90% effective in protecting people from the coronavirus. The news boosted hopes that we might be turning a corner in the fight against COVID-19. But it's important to point out this is early data, and the trial will continue into December. Pfizer has already started manufacturing the vaccine for mass distribution. The company is expected to supply up to 50 million vaccine doses worldwide in 2020 and up to 1.3 billion doses in 2021.